zileuton has been researched along with 2019 Novel Coronavirus Disease in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Andrade, ACDSP; Barbosa, CLN; Costa, VV; Cruz, JS; da Silva, BLV; da Silva, GSF; de Souza-Costa, LP; Ferreira, R; Machado, FS; Oliveira, FBR; Oliveira, NFM; Pereira, RDD; Porto, SLT; Queiroz-Junior, CM; Rabelo, RAN; Santos, FRDS; Teixeira, MM; Umezu, HL | 1 |
Citron, F; Deem, AK; Genovese, G; Perelli, L; Viale, A | 1 |
2 other study(ies) available for zileuton and 2019 Novel Coronavirus Disease
Article | Year |
---|---|
A 5-Lipoxygenase Inhibitor, Zileuton, Modulates Host Immune Responses and Improves Lung Function in a Model of Severe Acute Respiratory Syndrome (SARS) Induced by
Topics: Animals; COVID-19; Disease Models, Animal; Humans; Immunity, Innate; Lipoxygenase Inhibitors; Lung; Mice; Mice, Transgenic; SARS-CoV-2; Weight Loss | 2023 |
Leukotrienes, a potential target for Covid-19.
Topics: Acetates; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Betacoronavirus; Coronavirus Infections; COVID-19; Cyclopropanes; Cytokine Release Syndrome; Humans; Hydroxyurea; Immunologic Factors; Indoles; Leukotrienes; Pandemics; Phenylcarbamates; Pneumonia, Viral; Quinolines; SARS-CoV-2; Severity of Illness Index; Sulfides; Sulfonamides; Tosyl Compounds | 2020 |